Poolbeg Pharma Past Earnings Performance
Past criteria checks 0/6
Poolbeg Pharma's earnings have been declining at an average annual rate of -25.6%, while the Pharmaceuticals industry saw earnings declining at 1.7% annually.
Key information
-25.6%
Earnings growth rate
-1.9%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | n/a |
Return on equity | -29.5% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12Revenue & Expenses BreakdownBeta
How Poolbeg Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 0 | -5 | 3 | 2 |
31 Mar 23 | 0 | -5 | 3 | 2 |
31 Dec 22 | 0 | -5 | 3 | 2 |
Quality Earnings: POLB is currently unprofitable.
Growing Profit Margin: POLB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if POLB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare POLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: POLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.7%).
Return on Equity
High ROE: POLB has a negative Return on Equity (-29.53%), as it is currently unprofitable.